A Phase 2 interventional study of Olaparib in Advanced Solid Neoplasms, sponsored by Merck Sharp & Dohme LLC. Active, not recruiting at 130 sites in 21 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-14.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study will evaluate the efficacy and safety of olaparib (MK-7339) monotherapy in participants with multiple types of advanced cancer (unresectable and/or metastatic) that: 1) have progressed or been intolerant to standard of care therapy; and 2) are positive for homologous recombination repair mutation (HRRm) or homologous recombination deficiency (HRD).
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
A female participant is eligible to participate if she is not pregnant or breastfeeding, and at least one of the following conditions applies:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Per protocol, participants with tumors that harbor known or suspected deleterious mutations in breast cancer susceptibility gene 1 or gene 2 (BRCA1/2) based on the Lynparza homologous recombination repair-homologous recombination deficiency (HRR-HRD) Assay, excluding breast and ovarian cancers, were considered BRCA1/2 mutated and enrolled into Cohort 1: BRCA1/2. Participants with known or suspected deleterious mutations in BRCA1/BRCA2 were enrolled into Cohort 1 whether or not they were homologous recombination repair mutated (HRRm) positive for the other protocol specified genes in the Lynparza HRR-HRD Assay, or whether they had loss of heterozygosity (LOH) protocol specified score of ≥16. Participants in Cohort 1: BRCA1/2 received oral olaparib, 300 mg twice daily (BID) continuously until documented disease progression or discontinuation criteria were met.
Drug: Olaparib
Per protocol, participants with tumors that do NOT have any known or suspected deleterious mutations in BRCA1/2, or any of the other protocol specified genes in the Lynparza HRR-HRD Assay (BRCA1/2 Non-mutated/HRR Non-mutated) but had a loss of heterozygosity (LOH) score greater than or equal to the protocol specified cutoff of 16, were considered homologous recombination deficiency positive (HRD+) and enrolled into Cohort 2: HRD+(BRCA1/2 non-mutated/HRR Non-mutated). Participants in Cohort 2: HRD+ (BRCA1/2 Non-mutated/HRR Non-mutated) received oral olaparib, 300 mg BID continuously until documented disease progression or discontinuation criteria were met.
Drug: Olaparib
Per protocol, participants with tumors that do NOT have any known or suspected deleterious mutations in BRCA1/2 but have known or suspected deleterious mutations in any of the other protocol specified genes in the Lynparza HRR-HRD Assay were considered homologous recombination repair mutated \[HRRm\] and were enrolled into Cohort 2: HRRm (BRCA1/2 Non-mutated). Participants in Cohort 2: HRRm (BRCA1/2 Non-mutated) received oral olaparib, 300 mg BID continuously until documented disease progression or discontinuation criteria were met.
Drug: Olaparib
Per protocol, participants with breast cancer tumors that harbor known or suspected deleterious somatic mutations in BRCA1/2 and do not harbor a germline BRCA1/2 mutation were enrolled into Cohort 3: somatic BRCA1/2 mutations (sBRCAm). Participants in Cohort3: sBRCAm Breast Cancer received oral olaparib, 300 mg BID continuously until documented disease progression or discontinuation criteria were met.
Drug: Olaparib
Olaparib 300 mg administered BID as two, 150 mg oral tablets.
Also known as: MK-7339, AZD2281, KU-0059436, LYNPARZA®
Cohorts 1, 2, 3: Objective Response Rate (ORR) as Assessed by Blinded Independent Central Review (BICR) Per Modified Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) or Prostate Cancer Working Group (PCWG)-Modified RECIST 1.1
ORR was defined as the percentage of participants who have a confirmed Complete Response (CR: disappearance of all target lesions) or Partial Response (PR: At least a 30% decrease in the sum of diameters of target lesions) as assessed by the BICR per modified RECIST 1.1. For participants with prostate cancer, response was assessed based on PCWG-modified RECIST 1.1 criteria (CR: soft tissue CR with no evidence of disease \[NED\] on bone scan; PR: soft tissue PR with non-progressive disease, non-evaluable \[NE\], or NED on bone scan, or soft tissue CR with non-progressive disease, or NE bone scan). Per protocol, RECIST 1.1 was modified to follow a maximum of 10 target lesions in total and a maximum of 5 target lesions per organ. The percentage of participants who experienced a CR or PR as assessed by BICR is presented.
Time frame: Up to approximately 78 months
Cohorts 1, 2, 3: Duration of Response (DOR) as Assessed by BICR According to Modified RECIST 1.1 or PCWG-Modified RECIST 1.1
For participants with confirmed CR (disappearance of all target lesions) or PR (≥30% decrease in sum of diameters of target lesions) as assessed by BICR per modified RECIST; or, for participants with prostate cancer, per PCWG-modified RECIST 1.1 (CR: soft tissue CR with NED on bone scan; PR: soft tissue PR with non-progressive disease, NE, or NED on bone scan, or soft tissue CR with non-progressive disease, or NE bone scan) DOR was defined as time from first documented CR or PR to progressive disease (PD) or death. Per protocol, RECIST 1.1 was modified to allow ≤10 target lesions total (up to 5 per organ). Per RECIST 1.1, PD was defined as ≥20% increase in the sum of diameters of target lesions and absolute increase of ≥5 mm. The appearance of ≥1 new lesions was also PD. Per PCWG, PD was ≥2 new bone lesions (not tumor flare) persisting ≥6 weeks. DOR is presented.
Time frame: Up to approximately 78 months
Cohorts 1, 2, 3: Overall Survival (OS)
OS was defined as the time from the date of the first dose of study treatment to the date of death due to any cause. OS will be reported for all participants.
Time frame: Up to approximately 78 months
Cohorts 1, 2, 3: Progression Free Survival (PFS) as Assessed by BICR Per Modified RECIST 1.1 or PCWG-Modified RECIST 1.1
PFS was defined as the time from first dose of study treatment to the first documented progressive disease (PD) as assessed by BICR per modified RECIST 1.1 or PCWG-modified RECIST 1.1 (for participants with prostate cancer), or death due to any cause, whichever occurred first. Per protocol, RECIST 1.1 was modified to allow ≤10 target lesions total (up to 5 per organ). Per RECIST 1.1, PD was defined as ≥20% increase in the sum of diameters of target lesions and the sum must also have demonstrated an absolute increase of ≥5 mm. The appearance of one or more new lesions was also considered PD. Per PCWG, PD was ≥2 new bone lesions, confirmed to not represent tumor flare, and persistent for ≥6 weeks. The PFS per modified RECIST 1.1/PCWG-modified RECIST 1.1 as assessed by BICR is presented.
Time frame: Up to approximately 78 months
Cohorts 1, 2, 3: Number of Participants Experiencing an Adverse Event (AE)
An AE is any unfavorable and unintended sign, symptom, or disease (new or exacerbated) in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants who experience an AE will be reported.
Time frame: Up to approximately 78 months
Cohorts 1, 2, 3: Number of Participants Who Discontinue Study Treatment Due to an AE
An AE is any unfavorable and unintended sign, symptom, or disease (new or exacerbated) in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants who discontinue study treatment due to an AE will be reported.
Time frame: Up to approximately 78 months
Combined Cohort 1+2: ORR as Assessed by BICR Per Modified RECIST 1.1 or PCWG-Modified RECIST 1.1 in Participants Who Are HRRm Positive
ORR is defined as the percentage of participants who have a confirmed Complete Response (CR: disappearance of all target lesions) or Partial Response (PR: At least a 30% decrease in the sum of diameters of target lesions) as assessed by the BICR per modified RECIST 1.1. For participants with prostate cancer, response will be assessed based on PCWG-modified RECIST 1.1 criteria (CR: soft tissue CR with NED on bone scan; PR: soft tissue PR with non-progressive disease, NE, or NED on bone scan, or soft tissue CR with non-progressive disease, or NE bone scan). Per protocol, RECIST 1.1 was modified to follow a maximum of 10 target lesions in total and a maximum of 5 target lesions per organ. Per protocol, the secondary ORR outcome measure analysis for HRRm positive participants in Cohort 1 (BRCA 1/2) \& Cohort 2 \[(HRRm, BRCA Non-mutated); (HRD+, HRR Non-mutated)\] combined, is presented here. Per protocol, Cohort 1 \& 2 were combined as a pre-specified secondary efficacy analysis population.
Time frame: Up to approximately 78 months
Combined Cohort 1+2: ORR as Assessed by BICR Per Modified RECIST 1.1 or PCWG-Modified RECIST 1.1 In Participants Who Are HRD Positive (HRD+)
ORR is defined as the percentage of participants who have a confirmed Complete Response (CR: disappearance of all target lesions) or Partial Response (PR: At least a 30% decrease in the sum of diameters of target lesions) as assessed by the BICR per modified RECIST 1.1. For participants with prostate cancer, response will be assessed based on PCWG-modified RECIST 1.1 criteria (CR: soft tissue CR with NED on bone scan; PR: soft tissue PR with non-progressive disease, NE, or NED on bone scan, or soft tissue CR with non-progressive disease, or NE bone scan). Per protocol, RECIST 1.1 was modified to follow a maximum of 10 target lesions in total and a maximum of 5 target lesions per organ. Per protocol, the secondary ORR outcome measure analysis for HRD+ participants in Cohort 1 (BRCA 1/2) and Cohort 2 \[(HRRm, BRCA Non-mutated); (HRD+, HRR Non-mutated)\] combined, is presented here. Per protocol, Cohort 1 and Cohort 2 were combined as a pre-specified secondary efficacy analysis population.
Time frame: Up to approximately 78 months
Combined Cohort 1+2: ORR as Assessed by BICR Per Modified RECIST 1.1 or PCWG-Modified RECIST 1.1 in All Combined Cohort 1+2 Participants Regardless of Biomarker Status
ORR is defined as the percentage of participants who have a confirmed Complete Response (CR: disappearance of all target lesions) or Partial Response (PR: At least a 30% decrease in the sum of diameters of target lesions) as assessed by the BICR per modified RECIST 1.1. For participants with prostate cancer, response will be assessed based on PCWG-modified RECIST 1.1 criteria (CR: soft tissue CR with no evidence of disease \[NED\] on bone scan; PR: soft tissue PR with non-progressive disease, non-evaluable \[NE\], or NED on bone scan, or soft tissue CR with non-progressive disease, or NE bone scan). Per protocol, RECIST 1.1 was modified to follow a maximum of 10 target lesions in total and a maximum of 5 target lesions per organ. Per protocol, the secondary ORR outcome measure analysis for all participants regardless of biomarker status in Cohort 1 (BRCA 1/2) and Cohort 2 (\[HRRm, BRCA Non-mutated\]; \[HRD+, HRR Non-mutated\]) combined, is presented here.
Time frame: Up to approximately 78 months
Combined Cohort 1+2: DOR as Assessed by BICR Per Modified RECIST 1.1 or PCWG-Modified RECIST 1.1 in Participants Who Are HRRm Positive
For participants with CR (disappearance of all target lesions) or PR (≥30% decrease in sum of diameters of target lesions) as assessed by BICR per modified RECIST; or, for participants with prostate cancer, per PCWG-modified RECIST 1.1 (CR: soft tissue CR with NED on bone scan; PR: soft tissue PR with non-progressive disease, NE, or NED on bone scan, or soft tissue CR with non-progressive disease, or NE bone scan) DOR was defined as time from first documented CR/PR to PD or death. Per protocol, RECIST 1.1 was modified to allow ≤10 target lesions (up to 5 per organ). Per RECIST 1.1, PD was defined as ≥20% increase in the sum of diameters of target lesions \& absolute increase of ≥5 mm or appearance of ≥1 new lesion. Per PCWG, PD was ≥2 new bone lesions (not tumor flare) persisting ≥6 weeks. DOR for HRRm positive participants with CR/PR in Cohort 1 \& 2 combined is presented.
Time frame: Up to approximately 78 months
Combined Cohort 1+2: DOR as Assessed by BICR Per Modified RECIST 1.1 or PCWG-Modified RECIST 1.1 In Participants Who Are HRD Positive (HRD+)
For participants with CR (disappearance of all target lesions) or PR (≥30% decrease in sum of diameters of target lesions) as assessed by BICR per modified RECIST; or, for participants with prostate cancer, per PCWG-modified RECIST 1.1 (CR: soft tissue CR with NED on bone scan; PR: soft tissue PR with non-progressive disease, NE, or NED on bone scan, or soft tissue CR with non-progressive disease, or NE bone scan) DOR was defined as time from first documented CR/PR to PD or death. Per protocol, RECIST 1.1 was modified to allow ≤10 target lesions (up to 5 per organ). Per RECIST 1.1, PD was defined as ≥20% increase in the sum of diameters of target lesions \& absolute increase of ≥5 mm or appearance of ≥1 new lesion. Per PCWG, PD was ≥2 new bone lesions (not tumor flare) persisting ≥6 weeks. DOR for HRD+ participants with CR/PR in Cohort 1 \& 2 combined is presented.
Time frame: Up to approximately 78 months
Combined Cohort 1+2: DOR as Assessed by BICR Per Modified RECIST 1.1 or PCWG-modified RECIST 1.1 in All Combined Cohort 1+2 Participants Regardless of Biomarker Status
For participants with CR (disappearance of all target lesions) or PR (≥30% decrease in sum of diameters of target lesions) as assessed by BICR per modified RECIST; or, for participants with prostate cancer, per PCWG-modified RECIST 1.1 (CR: soft tissue CR with NED on bone scan; PR: soft tissue PR with non-progressive disease, NE, or NED on bone scan, or soft tissue CR with non-progressive disease, or NE bone scan) DOR was defined as time from first documented CR/PR to PD or death. Per protocol, RECIST 1.1 was modified to allow ≤10 target lesions (up to 5 per organ). Per RECIST 1.1, PD was defined as ≥20% increase in the sum of diameters of target lesions \& absolute increase of ≥5 mm or appearance of ≥1 new lesion. Per PCWG, PD was ≥2 new bone lesions (not tumor flare) persisting ≥6 weeks. DOR for all participants in Cohort 1 \& 2 combined with CR/PR is presented.
Time frame: Up to approximately 78 months
Combined Cohort 1+2: OS in Participants Who Are HRRm Positive
OS was defined as the time from the date of the first dose of study treatment to the date of death due to any cause. Per protocol, the secondary OS outcome measure analysis for HRRm positive participants in Cohort 1 (BRCA 1/2) and Cohort 2 \[(HRRm, BRCA Non-mutated); (HRD+, HRR Non-mutated)\] combined, will be presented. Per protocol, Cohort 1 and Cohort 2 will be combined as a pre-specified secondary efficacy analysis.
Time frame: Up to approximately 78 months
Combined Cohort 1+2: OS in Participants Who Are HRD Positive (HRD+)
OS was defined as the time from the date of the first dose of study treatment to the date of death due to any cause. Per protocol, the secondary OS outcome measure analysis for HRD+ participants in Cohort 1 (BRCA 1/2) and Cohort 2 \[(HRRm, BRCA Non-mutated); (HRD+, HRR Non-mutated)\] combined, will be presented. Per protocol, Cohort 1 and Cohort 2 will be combined as a pre-specified secondary efficacy analysis.
Time frame: Up to approximately 78 months
Combined Cohort 1+2: OS in All Combined Cohort 1+2 Participants Regardless of Biomarker Status
OS was defined as the time from the date of the first dose of study treatment to the date of death due to any cause. Per protocol, the secondary OS outcome measure analysis for all participants regardless of biomarker status in Cohort 1 (BRCA 1/2) and Cohort 2 \[(HRRm, BRCA Non-mutated); (HRD+, HRR Non-mutated)\] combined, will be presented. Per protocol, Cohort 1 and Cohort 2 will be combined as a pre-specified secondary efficacy analysis.
Time frame: Up to approximately 78 months
Combined Cohort 1+2: PFS as Assessed by BICR Per Modified RECIST 1.1 or PCWG-Modified RECIST 1.1 in Participants Who Are HRRm Positive
PFS was defined as the time from first dose of study treatment to the first documented progressive disease (PD) as assessed by BICR per modified RECIST 1.1 or PCWG-modified RECIST 1.1 (for participants with prostate cancer), or death due to any cause, whichever occurred first. Per protocol, RECIST 1.1 was modified to allow ≤10 target lesions total (up to 5 per organ). Per RECIST 1.1, PD was defined as ≥20% increase in the sum of diameters of target lesions and the sum must also have demonstrated an absolute increase of ≥5 mm. The appearance of one or more new lesions was also considered PD. Per PCWG, PD was ≥2 new bone lesions, confirmed to not represent tumor flare, and persistent for ≥6 weeks. Per protocol, the PFS analysis for HRRm positive participants in Cohort 1 and Cohort 2 combined is presented here.
Time frame: Up to approximately 78 months
Combined Cohort 1+2: PFS as Assessed by BICR Per Modified RECIST 1.1 or PCWG-Modified RECIST 1.1 in Participants Who Are HRD Positive (HRD+)
PFS was defined as the time from first dose of study treatment to the first documented progressive disease (PD) as assessed by BICR per modified RECIST 1.1 or PCWG-modified RECIST 1.1 (for participants with prostate cancer), or death due to any cause, whichever occurred first. Per protocol, RECIST 1.1 was modified to allow ≤10 target lesions total (up to 5 per organ). Per RECIST 1.1, PD was defined as ≥20% increase in the sum of diameters of target lesions and the sum must also have demonstrated an absolute increase of ≥5 mm. The appearance of one or more new lesions was also considered PD. Per PCWG, PD was ≥2 new bone lesions, confirmed to not represent tumor flare, and persistent for ≥6 weeks. Per protocol, the PFS analysis for HRD+ participants in Cohort 1 and Cohort 2 combined is presented here.
Time frame: Up to approximately 78 months
Combined Cohort 1+2: PFS as Assessed by BICR Per Modified RECIST 1.1 or PCWG-Modified RECIST 1.1 in All Combined Cohort 1+2 Participants Regardless of Biomarker Status
PFS was defined as the time from first dose of study treatment to the first documented PD as assessed by BICR per modified RECIST 1.1 or PCWG-modified RECIST 1.1 (for participants with prostate cancer), or death due to any cause, whichever occurred first. Per protocol, RECIST 1.1 was modified to allow ≤10 target lesions total (up to 5 per organ). Per RECIST 1.1, PD was defined as ≥20% increase in the sum of diameters of target lesions and the sum must also have demonstrated an absolute increase of ≥5 mm. The appearance of one or more new lesions was also considered PD. Per PCWG, PD was ≥2 new bone lesions, confirmed to not represent tumor flare, and persistent for ≥6 weeks. Per protocol, the PFS analysis for all participants regardless of biomarker status in Cohort 1 \& 2 is presented here.
Time frame: Up to approximately 78 months
Participants With BRCA1/2 Non-Mutated Ovarian Cancer: Time to Earliest Progression by Cancer Antigen-125 (CA-125)
Time to earliest progression by CA-125 was defined as the time from first dose to progression based on CA-125. For participants with BRCA1/2 non-mutated ovarian cancer only, progression by CA-125 was defined as either CA-125 ≥2× upper limit normal (ULN) on 2 occasions 1 week apart or, for participants with elevated CA-125 (≥ULN) at baseline, ≥2× the nadir value on 2 occasions 1 week apart. Time to earliest progression based on CA-125 is presented.
Time frame: Up to approximately 78 months
Participants With Prostate Cancer: Prostate-Specific Antigen (PSA) Response Rate
PSA response was defined as a reduction in PSA level ≥50% from baseline measured twice at least 3 weeks apart. For participants with prostate cancer with baseline PSA measurements available, the PSA response rate as assessed is presented.
Time frame: Up to approximately 78 months
Cohort 3: PFS2 as Assessed by the Investigator in Participants With sBRCAm Breast Cancer
PFS2 was defined as the time from the first dose of study medication to subsequent disease progression on next-line treatment or death due to any cause, whichever occurred first, as assessed by the investigator. PFS2 for participants with sBRCAm breast cancer in Cohort 3 will be reported.
Time frame: Up to approximately 78 months
| Milestone | Cohort 1: BRCA1/2 Mutated | Cohort 2: HRD+, HRR Non-mutated | Cohort 2: HRRm, BRCA1/2 Non-mutated | Cohort 3: sBRCAm Breast Cancer |
|---|---|---|---|---|
| Started | 88 | 93 | 141 | 7 |
| Treated | 86 | 92 | 141 | 7 |
| Efficacy analysis population | 86 | 90 | 140 | 7 |
| Completed | 0 | 0 | 0 | 0 |
| Not completed | 88 | 93 | 141 | 7 |
| Withdrew: Randomized by mistake without study treatment | 2 | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 3 | 3 | 2 | 0 |
| Withdrew: Death | 77 | 84 | 132 | 4 |
| Withdrew: Lost to follow-up | 0 | 0 | 1 | 0 |
| Withdrew: Ongoing | 6 | 5 | 6 | 3 |
ORR was defined as the percentage of participants who have a confirmed Complete Response (CR: disappearance of all target lesions) or Partial Response (PR: At least a 30% decrease in the sum of diameters of target lesions) as assessed by the BICR per modified RECIST 1.1. For participants with prostate cancer, response was assessed based on PCWG-modified RECIST 1.1 criteria (CR: soft tissue CR with no evidence of disease \[NED\] on bone scan; PR: soft tissue PR with non-progressive disease, non-evaluable \[NE\], or NED on bone scan, or soft tissue CR with non-progressive disease, or NE bone scan). Per protocol, RECIST 1.1 was modified to follow a maximum of 10 target lesions in total and a maximum of 5 target lesions per organ. The percentage of participants who experienced a CR or PR as assessed by BICR is presented.
| Percentage of participants | Cohort 1: BRCA1/2 Mutated | Cohort 2: HRD+, HRR Non-mutated | Cohort 2: HRRm, BRCA1/2 Non-mutated | Cohort 3: sBRCAm Breast Cancer |
|---|---|---|---|---|
| Cohorts 1, 2, 3: Objective Response Rate (ORR) as Assessed by Blinded Independent Central Review (BICR) Per Modified Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) or Prostate Cancer Working Group (PCWG)-Modified RECIST 1.1 | 16.3 (9.2 to 25.8) | 8.9 (3.9 to 16.8) | 8.6 (4.5 to 14.5) | 28.6 (3.7 to 71.0) |
For participants with confirmed CR (disappearance of all target lesions) or PR (≥30% decrease in sum of diameters of target lesions) as assessed by BICR per modified RECIST; or, for participants with prostate cancer, per PCWG-modified RECIST 1.1 (CR: soft tissue CR with NED on bone scan; PR: soft tissue PR with non-progressive disease, NE, or NED on bone scan, or soft tissue CR with non-progressive disease, or NE bone scan) DOR was defined as time from first documented CR or PR to progressive disease (PD) or death. Per protocol, RECIST 1.1 was modified to allow ≤10 target lesions total (up to 5 per organ). Per RECIST 1.1, PD was defined as ≥20% increase in the sum of diameters of target lesions and absolute increase of ≥5 mm. The appearance of ≥1 new lesions was also PD. Per PCWG, PD was ≥2 new bone lesions (not tumor flare) persisting ≥6 weeks. DOR is presented.
| Months | Cohort 1: BRCA1/2 Mutated | Cohort 2: HRD+, HRR Non-mutated | Cohort 2: HRRm, BRCA1/2 Non-mutated | Cohort 3: sBRCAm Breast Cancer |
|---|---|---|---|---|
| Cohorts 1, 2, 3: Duration of Response (DOR) as Assessed by BICR According to Modified RECIST 1.1 or PCWG-Modified RECIST 1.1 | 18.4 (5.1 to NA) | 9.7 (3.8 to NA) | 7.3 (5.6 to 18.8) | NA (NA to NA) |
OS was defined as the time from the date of the first dose of study treatment to the date of death due to any cause. OS will be reported for all participants.
Results for this outcome have not been posted.
PFS was defined as the time from first dose of study treatment to the first documented progressive disease (PD) as assessed by BICR per modified RECIST 1.1 or PCWG-modified RECIST 1.1 (for participants with prostate cancer), or death due to any cause, whichever occurred first. Per protocol, RECIST 1.1 was modified to allow ≤10 target lesions total (up to 5 per organ). Per RECIST 1.1, PD was defined as ≥20% increase in the sum of diameters of target lesions and the sum must also have demonstrated an absolute increase of ≥5 mm. The appearance of one or more new lesions was also considered PD. Per PCWG, PD was ≥2 new bone lesions, confirmed to not represent tumor flare, and persistent for ≥6 weeks. The PFS per modified RECIST 1.1/PCWG-modified RECIST 1.1 as assessed by BICR is presented.
| Months | Cohort 1: BRCA1/2 Mutated | Cohort 2: HRD+, HRR Non-mutated | Cohort 2: HRRm, BRCA1/2 Non-mutated | Cohort 3: sBRCAm Breast Cancer |
|---|---|---|---|---|
| Cohorts 1, 2, 3: Progression Free Survival (PFS) as Assessed by BICR Per Modified RECIST 1.1 or PCWG-Modified RECIST 1.1 | 3.2 (1.9 to 4.7) | 2.0 (1.9 to 3.4) | 3.3 (1.9 to 3.7) | 4.2 (1.4 to NA) |
An AE is any unfavorable and unintended sign, symptom, or disease (new or exacerbated) in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants who experience an AE will be reported.
Results for this outcome have not been posted.
An AE is any unfavorable and unintended sign, symptom, or disease (new or exacerbated) in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants who discontinue study treatment due to an AE will be reported.
Results for this outcome have not been posted.
ORR is defined as the percentage of participants who have a confirmed Complete Response (CR: disappearance of all target lesions) or Partial Response (PR: At least a 30% decrease in the sum of diameters of target lesions) as assessed by the BICR per modified RECIST 1.1. For participants with prostate cancer, response will be assessed based on PCWG-modified RECIST 1.1 criteria (CR: soft tissue CR with NED on bone scan; PR: soft tissue PR with non-progressive disease, NE, or NED on bone scan, or soft tissue CR with non-progressive disease, or NE bone scan). Per protocol, RECIST 1.1 was modified to follow a maximum of 10 target lesions in total and a maximum of 5 target lesions per organ. Per protocol, the secondary ORR outcome measure analysis for HRRm positive participants in Cohort 1 (BRCA 1/2) \& Cohort 2 \[(HRRm, BRCA Non-mutated); (HRD+, HRR Non-mutated)\] combined, is presented here. Per protocol, Cohort 1 \& 2 were combined as a pre-specified secondary efficacy analysis population.
| Percentage of Participants | Combined Cohort 1+2: All HRRm Positive Participants |
|---|---|
| Combined Cohort 1+2: ORR as Assessed by BICR Per Modified RECIST 1.1 or PCWG-Modified RECIST 1.1 in Participants Who Are HRRm Positive | 11.5 (7.7 to 16.4) |
ORR is defined as the percentage of participants who have a confirmed Complete Response (CR: disappearance of all target lesions) or Partial Response (PR: At least a 30% decrease in the sum of diameters of target lesions) as assessed by the BICR per modified RECIST 1.1. For participants with prostate cancer, response will be assessed based on PCWG-modified RECIST 1.1 criteria (CR: soft tissue CR with NED on bone scan; PR: soft tissue PR with non-progressive disease, NE, or NED on bone scan, or soft tissue CR with non-progressive disease, or NE bone scan). Per protocol, RECIST 1.1 was modified to follow a maximum of 10 target lesions in total and a maximum of 5 target lesions per organ. Per protocol, the secondary ORR outcome measure analysis for HRD+ participants in Cohort 1 (BRCA 1/2) and Cohort 2 \[(HRRm, BRCA Non-mutated); (HRD+, HRR Non-mutated)\] combined, is presented here. Per protocol, Cohort 1 and Cohort 2 were combined as a pre-specified secondary efficacy analysis population.
| Percentage of Participants | Combined Cohort 1 + Cohort 2: All HRD Positive (HRD+) Participants |
|---|---|
| Combined Cohort 1+2: ORR as Assessed by BICR Per Modified RECIST 1.1 or PCWG-Modified RECIST 1.1 In Participants Who Are HRD Positive (HRD+) | 14.1 (9.6 to 19.8) |
ORR is defined as the percentage of participants who have a confirmed Complete Response (CR: disappearance of all target lesions) or Partial Response (PR: At least a 30% decrease in the sum of diameters of target lesions) as assessed by the BICR per modified RECIST 1.1. For participants with prostate cancer, response will be assessed based on PCWG-modified RECIST 1.1 criteria (CR: soft tissue CR with no evidence of disease \[NED\] on bone scan; PR: soft tissue PR with non-progressive disease, non-evaluable \[NE\], or NED on bone scan, or soft tissue CR with non-progressive disease, or NE bone scan). Per protocol, RECIST 1.1 was modified to follow a maximum of 10 target lesions in total and a maximum of 5 target lesions per organ. Per protocol, the secondary ORR outcome measure analysis for all participants regardless of biomarker status in Cohort 1 (BRCA 1/2) and Cohort 2 (\[HRRm, BRCA Non-mutated\]; \[HRD+, HRR Non-mutated\]) combined, is presented here.
| Percentage of Participants | Combined Cohort 1 + 2: All Cohort 1 and Cohort 2 Participants Regardless of Biomarker Status |
|---|---|
| Combined Cohort 1+2: ORR as Assessed by BICR Per Modified RECIST 1.1 or PCWG-Modified RECIST 1.1 in All Combined Cohort 1+2 Participants Regardless of Biomarker Status | 10.8 (7.6 to 14.7) |
For participants with CR (disappearance of all target lesions) or PR (≥30% decrease in sum of diameters of target lesions) as assessed by BICR per modified RECIST; or, for participants with prostate cancer, per PCWG-modified RECIST 1.1 (CR: soft tissue CR with NED on bone scan; PR: soft tissue PR with non-progressive disease, NE, or NED on bone scan, or soft tissue CR with non-progressive disease, or NE bone scan) DOR was defined as time from first documented CR/PR to PD or death. Per protocol, RECIST 1.1 was modified to allow ≤10 target lesions (up to 5 per organ). Per RECIST 1.1, PD was defined as ≥20% increase in the sum of diameters of target lesions \& absolute increase of ≥5 mm or appearance of ≥1 new lesion. Per PCWG, PD was ≥2 new bone lesions (not tumor flare) persisting ≥6 weeks. DOR for HRRm positive participants with CR/PR in Cohort 1 \& 2 combined is presented.
| Months | Combined Cohort 1+2: All HRRm Positive Participants |
|---|---|
| Combined Cohort 1+2: DOR as Assessed by BICR Per Modified RECIST 1.1 or PCWG-Modified RECIST 1.1 in Participants Who Are HRRm Positive | 17.5 (7.0 to 19.9) |
For participants with CR (disappearance of all target lesions) or PR (≥30% decrease in sum of diameters of target lesions) as assessed by BICR per modified RECIST; or, for participants with prostate cancer, per PCWG-modified RECIST 1.1 (CR: soft tissue CR with NED on bone scan; PR: soft tissue PR with non-progressive disease, NE, or NED on bone scan, or soft tissue CR with non-progressive disease, or NE bone scan) DOR was defined as time from first documented CR/PR to PD or death. Per protocol, RECIST 1.1 was modified to allow ≤10 target lesions (up to 5 per organ). Per RECIST 1.1, PD was defined as ≥20% increase in the sum of diameters of target lesions \& absolute increase of ≥5 mm or appearance of ≥1 new lesion. Per PCWG, PD was ≥2 new bone lesions (not tumor flare) persisting ≥6 weeks. DOR for HRD+ participants with CR/PR in Cohort 1 \& 2 combined is presented.
| Months | Combined Cohort 1 + 2: All HRD Positive (HRD+) Particiipants |
|---|---|
| Combined Cohort 1+2: DOR as Assessed by BICR Per Modified RECIST 1.1 or PCWG-Modified RECIST 1.1 In Participants Who Are HRD Positive (HRD+) | 17.5 (7.5 to 20.2) |
For participants with CR (disappearance of all target lesions) or PR (≥30% decrease in sum of diameters of target lesions) as assessed by BICR per modified RECIST; or, for participants with prostate cancer, per PCWG-modified RECIST 1.1 (CR: soft tissue CR with NED on bone scan; PR: soft tissue PR with non-progressive disease, NE, or NED on bone scan, or soft tissue CR with non-progressive disease, or NE bone scan) DOR was defined as time from first documented CR/PR to PD or death. Per protocol, RECIST 1.1 was modified to allow ≤10 target lesions (up to 5 per organ). Per RECIST 1.1, PD was defined as ≥20% increase in the sum of diameters of target lesions \& absolute increase of ≥5 mm or appearance of ≥1 new lesion. Per PCWG, PD was ≥2 new bone lesions (not tumor flare) persisting ≥6 weeks. DOR for all participants in Cohort 1 \& 2 combined with CR/PR is presented.
| Months | Combined Cohort 1 + 2: All Cohort 1 and Cohort 2 Participants Regardless of Biomarker Status |
|---|---|
| Combined Cohort 1+2: DOR as Assessed by BICR Per Modified RECIST 1.1 or PCWG-modified RECIST 1.1 in All Combined Cohort 1+2 Participants Regardless of Biomarker Status | 16.0 (7.0 to 19.9) |
OS was defined as the time from the date of the first dose of study treatment to the date of death due to any cause. Per protocol, the secondary OS outcome measure analysis for HRRm positive participants in Cohort 1 (BRCA 1/2) and Cohort 2 \[(HRRm, BRCA Non-mutated); (HRD+, HRR Non-mutated)\] combined, will be presented. Per protocol, Cohort 1 and Cohort 2 will be combined as a pre-specified secondary efficacy analysis.
Results for this outcome have not been posted.
OS was defined as the time from the date of the first dose of study treatment to the date of death due to any cause. Per protocol, the secondary OS outcome measure analysis for HRD+ participants in Cohort 1 (BRCA 1/2) and Cohort 2 \[(HRRm, BRCA Non-mutated); (HRD+, HRR Non-mutated)\] combined, will be presented. Per protocol, Cohort 1 and Cohort 2 will be combined as a pre-specified secondary efficacy analysis.
Results for this outcome have not been posted.
OS was defined as the time from the date of the first dose of study treatment to the date of death due to any cause. Per protocol, the secondary OS outcome measure analysis for all participants regardless of biomarker status in Cohort 1 (BRCA 1/2) and Cohort 2 \[(HRRm, BRCA Non-mutated); (HRD+, HRR Non-mutated)\] combined, will be presented. Per protocol, Cohort 1 and Cohort 2 will be combined as a pre-specified secondary efficacy analysis.
Results for this outcome have not been posted.
PFS was defined as the time from first dose of study treatment to the first documented progressive disease (PD) as assessed by BICR per modified RECIST 1.1 or PCWG-modified RECIST 1.1 (for participants with prostate cancer), or death due to any cause, whichever occurred first. Per protocol, RECIST 1.1 was modified to allow ≤10 target lesions total (up to 5 per organ). Per RECIST 1.1, PD was defined as ≥20% increase in the sum of diameters of target lesions and the sum must also have demonstrated an absolute increase of ≥5 mm. The appearance of one or more new lesions was also considered PD. Per PCWG, PD was ≥2 new bone lesions, confirmed to not represent tumor flare, and persistent for ≥6 weeks. Per protocol, the PFS analysis for HRRm positive participants in Cohort 1 and Cohort 2 combined is presented here.
| Months | Combined Cohort 1+2: All HRRm Positive Participants |
|---|---|
| Combined Cohort 1+2: PFS as Assessed by BICR Per Modified RECIST 1.1 or PCWG-Modified RECIST 1.1 in Participants Who Are HRRm Positive | 3.2 (1.9 to 3.7) |
PFS was defined as the time from first dose of study treatment to the first documented progressive disease (PD) as assessed by BICR per modified RECIST 1.1 or PCWG-modified RECIST 1.1 (for participants with prostate cancer), or death due to any cause, whichever occurred first. Per protocol, RECIST 1.1 was modified to allow ≤10 target lesions total (up to 5 per organ). Per RECIST 1.1, PD was defined as ≥20% increase in the sum of diameters of target lesions and the sum must also have demonstrated an absolute increase of ≥5 mm. The appearance of one or more new lesions was also considered PD. Per PCWG, PD was ≥2 new bone lesions, confirmed to not represent tumor flare, and persistent for ≥6 weeks. Per protocol, the PFS analysis for HRD+ participants in Cohort 1 and Cohort 2 combined is presented here.
| Months | Combined Cohort 1+2: All HRD Positive (HRD+) Participants |
|---|---|
| Combined Cohort 1+2: PFS as Assessed by BICR Per Modified RECIST 1.1 or PCWG-Modified RECIST 1.1 in Participants Who Are HRD Positive (HRD+) | 2.7 (1.9 to 3.6) |
PFS was defined as the time from first dose of study treatment to the first documented PD as assessed by BICR per modified RECIST 1.1 or PCWG-modified RECIST 1.1 (for participants with prostate cancer), or death due to any cause, whichever occurred first. Per protocol, RECIST 1.1 was modified to allow ≤10 target lesions total (up to 5 per organ). Per RECIST 1.1, PD was defined as ≥20% increase in the sum of diameters of target lesions and the sum must also have demonstrated an absolute increase of ≥5 mm. The appearance of one or more new lesions was also considered PD. Per PCWG, PD was ≥2 new bone lesions, confirmed to not represent tumor flare, and persistent for ≥6 weeks. Per protocol, the PFS analysis for all participants regardless of biomarker status in Cohort 1 \& 2 is presented here.
| Months | Combined Cohort 1+2: All Cohort 1 and Cohort 2 Participants Regardless of Biomarker Status |
|---|---|
| Combined Cohort 1+2: PFS as Assessed by BICR Per Modified RECIST 1.1 or PCWG-Modified RECIST 1.1 in All Combined Cohort 1+2 Participants Regardless of Biomarker Status | 2.6 (1.9 to 3.5) |
Time to earliest progression by CA-125 was defined as the time from first dose to progression based on CA-125. For participants with BRCA1/2 non-mutated ovarian cancer only, progression by CA-125 was defined as either CA-125 ≥2× upper limit normal (ULN) on 2 occasions 1 week apart or, for participants with elevated CA-125 (≥ULN) at baseline, ≥2× the nadir value on 2 occasions 1 week apart. Time to earliest progression based on CA-125 is presented.
| Months | Participants With BRCA1/2 Non-Mutated Ovarian Cancer |
|---|---|
| Participants With BRCA1/2 Non-Mutated Ovarian Cancer: Time to Earliest Progression by Cancer Antigen-125 (CA-125) | 9.2 (5.4 to NA) |
PSA response was defined as a reduction in PSA level ≥50% from baseline measured twice at least 3 weeks apart. For participants with prostate cancer with baseline PSA measurements available, the PSA response rate as assessed is presented.
| Percentage of Participants | Participants With Prostate Cancer |
|---|---|
| Participants With Prostate Cancer: Prostate-Specific Antigen (PSA) Response Rate | 37.5 (21.1 to 56.3) |
PFS2 was defined as the time from the first dose of study medication to subsequent disease progression on next-line treatment or death due to any cause, whichever occurred first, as assessed by the investigator. PFS2 for participants with sBRCAm breast cancer in Cohort 3 will be reported.
Results for this outcome have not been posted.
Collected over Up to approximately 78 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cohort 1: BRCA1/2 Mutated | 79/88 (89.8%) | 25/86 (29.1%) | 76/86 (88.4%) |
| Cohort 2: HRD+, HRR Non-mutated | 86/93 (92.5%) | 26/92 (28.3%) | 80/92 (87%) |
| Cohort 2: HRRm, BRCA1/2 Non-mutated | 133/141 (94.3%) | 44/141 (31.2%) | 123/141 (87.2%) |
| Cohort 3: sBRCAm Breast Cancer | 4/7 (57.1%) | 1/7 (14.3%) | 7/7 (100%) |
| Event | Cohort 1: BRCA1/2 Mutated | Cohort 2: HRD+, HRR Non-mutated | Cohort 2: HRRm, BRCA1/2 Non-mutated | Cohort 3: sBRCAm Breast Cancer |
|---|---|---|---|---|
| Humerus fractureInjury, poisoning and procedural complications | 0/86 | 0/92 | 0/141 | 1/7 |
| AnaemiaBlood and lymphatic system disorders | 2/86 | 4/92 | 1/141 | 0/7 |
| PneumoniaInfections and infestations | 3/86 | 4/92 | 5/141 | 0/7 |
| Abdominal painGastrointestinal disorders | 2/86 | 0/92 | 0/141 | 0/7 |
| Basal cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 2/86 | 0/92 | 0/141 | 0/7 |
| Pleural effusionRespiratory, thoracic and mediastinal disorders | 2/86 | 2/92 | 0/141 | 0/7 |
| Intestinal obstructionGastrointestinal disorders | 1/86 | 1/92 | 3/141 | 0/7 |
| SepsisInfections and infestations | 0/86 | 1/92 | 3/141 | 0/7 |
| Upper gastrointestinal haemorrhageGastrointestinal disorders | 0/86 | 0/92 | 2/141 | 0/7 |
| Soft tissue infectionInfections and infestations | 0/86 | 0/92 | 2/141 | 0/7 |
| Event | Cohort 1: BRCA1/2 Mutated | Cohort 2: HRD+, HRR Non-mutated | Cohort 2: HRRm, BRCA1/2 Non-mutated | Cohort 3: sBRCAm Breast Cancer |
|---|---|---|---|---|
| NauseaGastrointestinal disorders | 40/86 | 37/92 | 59/141 | 2/7 |
| AnaemiaBlood and lymphatic system disorders | 34/86 | 34/92 | 49/141 | 3/7 |
| DiarrhoeaGastrointestinal disorders | 9/86 | 14/92 | 20/141 | 2/7 |
| VomitingGastrointestinal disorders | 23/86 | 20/92 | 29/141 | 2/7 |
| Decreased appetiteMetabolism and nutrition disorders | 23/86 | 15/92 | 28/141 | 2/7 |
| FatigueGeneral disorders | 23/86 | 19/92 | 23/141 | 0/7 |
| AstheniaGeneral disorders | 10/86 | 23/92 | 20/141 | 0/7 |
| ConstipationGastrointestinal disorders | 17/86 | 12/92 | 16/141 | 0/7 |
| NeutropeniaBlood and lymphatic system disorders | 5/86 | 6/92 | 4/141 | 1/7 |
| Abdominal pain upperGastrointestinal disorders | 5/86 | 6/92 | 7/141 | 1/7 |
| Age, Continuous(years) | Cohort 1: BRCA1/2 Mutated | Cohort 2: HRD+, HRR Non-mutated | Cohort 2: HRRm, BRCA1/2 Non-mutated | Cohort 3: sBRCAm Breast Cancer | Total |
|---|---|---|---|---|---|
| Mean | 61.2 ± 11.0 | 57.9 ± 12.1 | 59.6 ± 12.3 | 53.4 ± 6.9 | 59.4 ± 11.9 |
| Sex: Female, Male(Participants) | Cohort 1: BRCA1/2 Mutated | Cohort 2: HRD+, HRR Non-mutated | Cohort 2: HRRm, BRCA1/2 Non-mutated | Cohort 3: sBRCAm Breast Cancer | Total |
|---|---|---|---|---|---|
| Female | 34 | 70 | 77 | 7 | 188 |
| Male | 54 | 23 | 64 | 0 | 141 |
| Ethnicity (NIH/OMB)(Participants) | Cohort 1: BRCA1/2 Mutated | Cohort 2: HRD+, HRR Non-mutated | Cohort 2: HRRm, BRCA1/2 Non-mutated | Cohort 3: sBRCAm Breast Cancer | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 16 | 28 | 30 | 3 | 77 |
| Not Hispanic or Latino | 68 | 60 | 104 | 4 | 236 |
| Unknown or Not Reported | 4 | 5 | 7 | 0 | 16 |
| Race (NIH/OMB)(Participants) | Cohort 1: BRCA1/2 Mutated | Cohort 2: HRD+, HRR Non-mutated | Cohort 2: HRRm, BRCA1/2 Non-mutated | Cohort 3: sBRCAm Breast Cancer | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 4 | 5 | 1 | 0 | 10 |
| Asian | 20 | 1 | 18 | 3 | 42 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 1 | 0 | 3 | 0 | 4 |
| White | 55 | 74 | 99 | 1 | 229 |
| More than one race | 3 | 9 | 14 | 3 | 29 |
| Unknown or Not Reported | 5 | 4 | 6 | 0 | 15 |
Showing the first 100 of 130 sites across 21 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf
Data sharing details ↗ · externaldatasharing-msd.com
Ran from Dec 2018 to primary completion in Aug 2025, 80 months.
Results were first posted in Aug 2026, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Olaparib